1
|
Decara J, Rivera P, Arrabal S, Vargas A, Serrano A, Pavón FJ, Dieguez C, Nogueiras R, Rodríguez de Fonseca F, Suárez J. Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats. Acta Physiol (Oxf) 2018; 222:e13008. [PMID: 29193738 DOI: 10.1111/apha.13008] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 11/13/2017] [Accepted: 11/23/2017] [Indexed: 12/19/2022]
Abstract
AIM To explore the cooperation of GLP-1 receptor and β3-adrenergic receptor (β3-AR)-mediated signalling in the control of fat mass/feeding behaviour by studying the effects of a combined therapy composed of the GLP-1R agonist liraglutide and the β3-AR agonist CL316243. METHODS The study included the analysis of key mechanisms regulating lipid/cholesterol metabolism, and thermogenesis in brown (BAT) and epididymal white (eWAT) adipose tissues, abdominal muscle and liver of male rats. RESULTS CL316243 (1 mg kg-1 ) and liraglutide (100 μg kg-1 ) co-administration over 6 days potentiated an overall negative energy balance (reduction in food intake, body weight gain, fat/non-fat mass ratio, liver fat content, and circulating levels of non-essential fatty acids, triglycerides, very low-density lipoprotein-cholesterol and leptin). These effects were accompanied by increased plasma levels of insulin and IL6. We also observed increased gene expression of uncoupling proteins regulating thermogenesis in BAT/eWAT (Ucp1) and muscle (Ucp2/3). Expression of transcription factor and enzymes involved either in de novo lipogenesis (Chrebp, Acaca, Fasn, Scd1, Insig1, Srebp1) or in fatty acid β-oxidation (Cpt1b) was enhanced in eWAT and/or muscle but decreased in BAT. Pparα and Pparγ, essentials in lipid flux/storage, were decreased in BAT/eWAT but increased in the muscle and liver. Cholesterol synthesis regulators (Insig2, Srebp2, Hmgcr) were particularly over-expressed in muscle. These GLP-1R/β3-AR-induced metabolic effects were associated with the downregulation of cAMP-dependent signalling pathways (PKA/AKT/AMPK). CONCLUSION Combined activation of GLP-1 and β3-ARs potentiate changes in peripheral pathways regulating lipid/cholesterol metabolism in a tissue-specific manner that favours a switch in energy availability/expenditure and may be useful for obesity treatment.
Collapse
Affiliation(s)
- J. Decara
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - P. Rivera
- Department of Endocrinology; Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús; Madrid Spain
| | - S. Arrabal
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - A. Vargas
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - A. Serrano
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - F. J. Pavón
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - C. Dieguez
- Department of Physiology; School of Medicine-CIMUS; University of Santiago De Compostela-Instituto De Investigación Sanitaria; Santiago De Compostela Spain
- CIBER OBN; Instituto de Salud Carlos III; Madrid Spain
| | - R. Nogueiras
- Department of Physiology; School of Medicine-CIMUS; University of Santiago De Compostela-Instituto De Investigación Sanitaria; Santiago De Compostela Spain
- CIBER OBN; Instituto de Salud Carlos III; Madrid Spain
| | - F. Rodríguez de Fonseca
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
| | - J. Suárez
- Instituto de Investigación Biomédica de Málaga (IBIMA); UGC Salud Mental; Universidad de Málaga, Hospital Universitario Regional de Málaga; Málaga Spain
- Departamento de Biología Celular; Genética y Fisiología; Facultad de Ciencias; IBIMA; Universidad de Málaga; Málaga Spain
| |
Collapse
|
2
|
Gavito AL, Cabello R, Suarez J, Serrano A, Pavón FJ, Vida M, Romero M, Pardo V, Bautista D, Arrabal S, Decara J, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Br J Pharmacol 2016; 173:1070-84. [PMID: 26750868 DOI: 10.1111/bph.13423] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Revised: 12/18/2015] [Accepted: 01/06/2016] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND AND PURPOSE Lipogenesis is intimately controlled by hormones and cytokines as well as nutritional conditions. IL-6 participates in the regulation of fatty acid metabolism in the liver. We investigated the role of IL-6 in mediating fasting/re-feeding changes in the expression of hepatic lipogenic enzymes. EXPERIMENTAL APPROACH Gene and protein expression of lipogenic enzymes were examined in livers of wild-type (WT) and IL-6-deficient (IL-6(-/-) ) mice during fasting and re-feeding conditions. Effects of exogenous IL-6 administration on gene expression of these enzymes were evaluated in vivo. The involvement of STAT3 in mediating these IL-6 responses was investigated by using siRNA in human HepG2 cells. KEY RESULTS During feeding, the up-regulation in the hepatic expression of lipogenic genes presented similar time kinetics in WT and IL-6(-/-) mice. During fasting, expression of lipogenic genes decreased gradually over time in both strains, although the initial drop was more marked in IL-6(-/-) mice. Protein levels of hepatic lipogenic enzymes were lower in IL-6(-/-) than in WT mice at the end of the fasting period. In WT, circulating IL-6 levels paralleled gene expression of hepatic lipogenic enzymes. IL-6 administration in vivo and in vitro showed that IL-6-mediated signalling was associated with the up-regulation of hepatic lipogenic enzyme genes. Moreover, silencing STAT3 in HepG2 cells attenuated IL-6 mediated up-regulation of lipogenic gene transcription levels. CONCLUSIONS AND IMPLICATIONS IL-6 sustains levels of hepatic lipogenic enzymes during fasting through activation of STAT3. Our findings indicate that clinical use of STAT3-associated signalling cytokines, particularly against steatosis, should be undertaken with caution.
Collapse
Affiliation(s)
- A L Gavito
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - R Cabello
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain
| | - J Suarez
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - A Serrano
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - F J Pavón
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - M Vida
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - M Romero
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain
| | - V Pardo
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, 28029, Spain.,Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, 28029, Spain
| | - D Bautista
- Unidad de Gestión Clínica de Anatomía Patológica, Hospital Regional Universitario de Málaga, Málaga 29010, Spain
| | - S Arrabal
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - J Decara
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - A L Cuesta
- Danish Diabetes Academy, Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
| | - A M Valverde
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, 28029, Spain.,Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, 28029, Spain
| | - F Rodríguez de Fonseca
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - E Baixeras
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| |
Collapse
|